Reference #18.11ff1302.1785014212.3c3a1cee
Ouder dan 18 jaar Mensen met een BMI van 27 tot 35 die willen afvallen en geen suikerziekte hebben
Type 2 diabetes trial results were published in The Lancet in 2023, showing meaningful improvements in blood sugar control alongside substantial weight loss
Such forward-looking statements include statements regarding, among other things, the expected initiation of a Phase 1 trial of RT-114 in 2025, the potential of the RaniPill platform to enable oral delivery of multiple obesity treatments and validation of such potential through preclinical data, the target product profile of semaglutide delivered via the RaniPill capsule, the novelty, convenience and attractiveness of a once-weekly oral semaglutide treatment for patients, Ranis confidence to continue building an obesity portfolio, the potential of a once-weekly oral version of semaglutide in the RaniPill capsule to deliver the same benefits as subcutaneous delivery and to impact patients lives, the sufficiency of Ranis cash reserves, and future financial performance
Many people have filed lawsuits against Novo Nordisk, saying using Wegovy for weight loss damaged their kidneys
